Analyst Ratings For Dechra Pharmaceuticals plc (LON:DPH)
Today, HSBC lowered its price target on Dechra Pharmaceuticals plc (LON:DPH) to GBX 2,700 per share.
There are 2 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Dechra Pharmaceuticals plc (LON:DPH) is Hold with a consensus target price of GBX 2,583.33 per share, a potential .
Some recent analyst ratings include
- 7/11/2017-Dechra Pharmaceuticals plc (LON:DPH) had its Hold rating reiterated by Stifel Nicolaus with a GBX 1,550 price target
- 7/6/2017-Dechra Pharmaceuticals plc (LON:DPH) had its Buy rating reiterated by Investec with a GBX 1,840 price target
- 7/6/2017-Dechra Pharmaceuticals plc (LON:DPH) had its Buy rating reiterated by N+1 Singer with a GBX 1,666 price target
About Dechra Pharmaceuticals plc (LON:DPH)
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Recent Trading Activity for Dechra Pharmaceuticals plc (LON:DPH)
Shares of Dechra Pharmaceuticals plc closed the previous trading session at 2,352.00 −38.00 1.59% with shares trading hands.
